MedTrace Logo

HW071021 Monotherapy in Patients With Advanced Solid Tumors

NCT06882135 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-12-29

No results posted yet for this study

Summary

This is a Phase I open-label study that will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HW071021 monotherapy in patients with advanced solid tumors.

Conditions

Interventions

DRUG

HW071021 Tablets

Administered orally at pre-specified doses once or twice daily.

Sponsors & Collaborators

  • Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

    lead INDUSTRY

Principal Investigators

  • Li Zhang, Doctor · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-28
Primary Completion
2026-09-30
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06882135 on ClinicalTrials.gov